Skip to content
    MTD
    Earnings call· Jun 2026(Q2 FY26)

    METTLER TOLEDO INTERNATIONAL INC/ Q2 FY26 earnings call MTD

    Jul 31, 2026 Source

    Executive summary

    Mettler-Toledo Q2 FY26 — Strong Organic Growth and Raised Full-Year Outlook

    Mettler-Toledo delivered strong Q2 FY26 results, driven by better-than-expected organic sales growth across its portfolio, particularly in China and emerging markets, and effective Spinnaker sales programs. The company raised its full-year guidance for both sales and adjusted EPS, reflecting improved market conditions and confidence in its strategic execution, while acknowledging potential geopolitical risks.

    Highlights

    5
    • Organic sales grew 4% in local currency, exceeding prior guidance of approximately 3%.

    • Adjusted EPS increased 14% year-over-year to $11.46.

    • China organic sales grew 9%, stronger than expected.

    • Emerging markets outside of China grew high single digits, representing approximately 18% of sales.

    • Adjusted gross margin expanded 90 basis points (excluding FX and acquisitions) to 59.3%.

    Concerns

    3
    • Middle East volatility could impact customer decision-making, though no change in behavior is currently observed.

    • Product inspection organic sales growth was modest (1%) due to the timing of customer projects, but expected to pick up in H2.

    • Americas growth was partly offset by timing of food retail and transportation and logistics project activity.

    Guidance & targets

    29
    CategoryTargetConfidence
    Full-year 2026 Local Currency Sales Growth
    Approximately 4% to 5%
    high materiality
    High
    Full-year 2026 Adjusted EPS
    $47.15 to $47.50
    high materiality
    High
    Full-year 2026 FX Impact on Sales Growth
    1% benefit
    medium materiality
    High
    Q3 2026 Local Currency Sales Growth
    Approximately 4%
    medium materiality
    High
    Q3 2026 Adjusted EPS
    $12 to $12.15
    high materiality
    High
    Q3 2026 FX Impact on Sales
    Neutral
    low materiality
    High
    Full-year 2026 Total Amortization
    Approximately $78 million
    low materiality
    High
    Full-year 2026 Purchased Intangible Amortization (pretax)
    $28 million
    low materiality
    High
    Full-year 2026 Interest Expense
    $67 million
    low materiality
    High
    Full-year 2026 Other Income
    Approximately $24 million
    low materiality
    High
    Full-year 2026 Tax Rate (before discrete items)
    19%
    medium materiality
    High
    Full-year 2026 Free Cash Flow
    Approximately $900 million
    high materiality
    High
    Full-year 2026 Share Repurchases
    $875 million
    high materiality
    High
    China Growth
    High single digit
    medium materiality
    High
    Lab Growth
    Mid-single digit
    medium materiality
    High
    Core Industrial Growth
    Low single digit
    medium materiality
    High
    Product Inspection Growth
    Mid-single digit
    medium materiality
    High
    Food Retail Growth
    Flat
    low materiality
    High
    Americas Growth
    Low to mid-single digit
    medium materiality
    High
    Europe Growth
    Low single digit
    medium materiality
    High
    Full-year Lab Growth
    Low to mid-single digit
    medium materiality
    High
    Full-year Core Industrial Growth
    Low to mid-single digit
    medium materiality
    High
    Full-year Product Inspection Growth
    High single digit
    medium materiality
    High
    Full-year Retail Growth
    Low to mid-single digit
    low materiality
    High
    Full-year Americas Growth
    Low single digit
    medium materiality
    High
    Full-year Europe Growth
    Low single digit
    medium materiality
    High
    Full-year China Growth
    High single digit
    medium materiality
    High
    H2 2026 Price Realization
    2.5% range
    medium materiality
    High
    Full-year 2026 Price Realization
    Approaching 3%
    medium materiality
    High

    Segment performance

    12
    SegmentRevenueYoYQoQMargin
    Company Total
    Exceeded prior guidance of approximately 3% local currency sales growth.
    Local currency growth: 6%Organic local currency growth: 4%Acquisitions contribution to sales growth: 1.5%
    $1 billion7% USD
    Americas
    Strong momentum in most lab product categories, core industrial automation solutions, and product inspection, offset by timing of food retail and transportation and logistics project activity.
    1% organic
    Europe
    Solid growth across most of the business, including strong growth in core industrial and food retail.
    4% organic
    Asia/Rest of World
    Very good growth across the portfolio and in most major markets.
    9% organic
    China
    Stronger than expected, led by industrial with double-digit growth, benefiting from biopharma, food, and battery investments. Lab growth was more modest.
    9% organic
    Emerging Markets (ex-China)
    Grew high single digits on average in local currencies over the last 5 years, above the company average.
    Sales as % of total: Approximately 18%
    High single digits
    Laboratory
    Good growth across most product areas, improving trends in biopharma, strong growth in process analytics and bioproduction. Analytical instruments and balances growth was strong.
    4% organic
    Industrial
    3% organic
    Core Industrial
    Did well with sales growth driven by strong demand for automation solutions, seeing strength across biopharma, food manufacturing, semiconductor, and new energy.
    4% organic
    Product Inspection
    Modest organic sales growth due to timing of customer projects, but expected to pick up in the second half. 70% of business is food manufacturing.
    1% organic
    Food Retail
    Better than expected due to the timing of project activity.
    11% organic
    Service
    Growing faster than products, exceeded $1 billion in revenues last year. Benefits from AI-supported knowledge base for service engineers.
    9% reported, 7% organic

    Operational metrics

    20
    Adjusted Gross Margin
    59.3%+30 bps YoY
    Q2 FY26
    R&D Expense
    $53 million+3% LC YoY
    Q2 FY26
    SG&A Expense
    $263 million+4% LC YoY
    Q2 FY26
    Adjusted Operating Profit
    $309 million+9% YoY
    Q2 FY26
    Adjusted Operating Margin
    29.3%+50 bps YoY
    Q2 FY26
    Adjusted EPS
    $11.46+14% YoY
    Q2 FY26
    Reported EPS
    $11.55vs. $9.76 prior year
    Q2 FY26
    Net Tariff Refund Benefit (EPS impact)
    $0.92
    Q2 FY26

    Included in reported EPS.

    Purchased Intangible Amortization (EPS impact)
    $0.26
    Q2 FY26

    Included in reported EPS.

    Restructuring Costs (EPS impact)
    $0.22
    Q2 FY26

    Included in reported EPS.

    Tax Headwind (EPS impact)
    $0.04
    Q2 FY26

    Included in reported EPS.

    Acquisition-related Charge (EPS impact)
    $0.31
    Q2 FY26

    Included in reported EPS.

    Days Sales Outstanding (DSO)
    35.6 days
    Q2 FY26
    Inventory Turns (ITO)
    4.2x
    Q2 FY26
    Operating Margin Expansion (ex-currency)
    60-70 bps
    FY26

    Expected for the full year 2026.

    Operating Margin Expansion (reported)
    10-20 bps
    FY26

    Expected for the full year 2026.

    Bioprocessing Sales as % of Total Sales
    Low double digit
    Q2 FY26

    Includes pro and part of industrial automation portfolio.

    Hot Segments Contribution to Sales
    Low single-digit
    Q2 FY26

    These segments are seeing good growth.

    Service Revenue
    Over $1 billion
    FY25

    Exceeded this amount for the first time last year.

    EU Chemical Segment Performance
    Bettervs. Q1 FY26
    Q2 FY26

    Still taking a more cautious stance due to energy cost fluctuations.

    Industry KPIs

    10
    MetricValueDetails
    FCF conversion ROIC$367 millionUSD
    Revenue EPS guidanceFY26 organic growth 3-4%, adjusted EPS $47.15-$47.50%, USD
    China revenue exposure9%%
    Pricing price realization3%%
    M a contribution synergies1.5%%
    Segment organic revenue growthAmericas +1%, Europe +4%, Asia/Rest of World +9%, Laboratory +4%, Industrial +3% (Core Industrial +4%, Product Inspection +1%), Food Retail +11%, Service +7%%
    Bioprocessing orders book to billGood growth
    Reshoring US manufacturing tailwindSeeing RFQs, early innings
    Instruments vs consumables services mixAnalytical instruments and laboratory balances growth strong; Pipette business returned to growth
    Organic core revenue growth by end marketPharma & Biotech: Improving trends, strong growth in process analytics and bioproduction; Semiconductor: Strong demand; Advanced Materials: Strong demand; Batteries: Strong demand; Food Manufacturing: 70% of Product Inspection business; Academic & Government: Starting to improve; Chemical: EU chemical results better in Q2, but cautious stance

    Product announcements

    4
    ProductTypeDetails
    New semiautomatic pipettelaunch
    New AutoChem solutionlaunch
    New products in lab product categorieslaunch
    New Product Inspection productslaunch

    Risks & headwinds

    3
    Middle East volatility impacting customer decision-makingOngoing

    Not quantified, but could impact customer decision-making should conditions significantly change.

    Mitigation: Not included in forecast; company remains agile and focused on execution.

    Challenging prior-year comparisons for Q3Q3 FY26

    Core industrial grew 10% organically in Q3 last year; Americas was up 9% organically in Q3 last year.

    Mitigation: Management feels good about momentum and guidance despite challenging comps.

    Energy cost fluctuations in EU chemical segmentOngoing

    Not quantified, but leads to a 'more cautious stance' on the overall segment.

    Mitigation: Will have easier comps in quarters to come.

    What to watch in Q3 FY26

    5

    China Lab Business Acceleration

    Second half of the year
    CurrentModest growth in Q2, industrial-led
    TargetPick up in H2, especially from biopharma and academia

    Why it matters

    Indicates broader recovery in a key growth market beyond industrial and confirms the effectiveness of strategic initiatives.

    For lab, the growth was a bit more modest. We expect continued improvement there also in the second half, both also from biopharma and maybe also academia will pick up towards the end of the year.

    Q&A highlights

    7

    Seeking details on the drivers of China's 9% growth, particularly the mix between industrial/non-pharma and lab/pharma, and expectations for sustained momentum.

    Patrick Kaltenbach stated China's growth was led by industrial (double-digit growth), benefiting from biopharma, food, and hot segments like battery investments. Lab growth was more modest but expected to improve in H2, with potential for academia funding. Shawn Vadala confirmed high single-digit growth expected for China in Q3 and full year, with good momentum from automation/digitalization.

    the growth has really been led by industrial, which had double-digit growth in China. We are benefiting from many of the core segments such as biopharma, but also food as well as the hot segments like investments in battery that is happening in China.

    asked by Dan Arias · answered by Patrick Kaltenbach

    2 min read7 chapters

    Detailed Narrative

    01

    Q2 Performance Highlights

    Mettler-Toledo reported strong Q2 results with 4% organic sales growth in local currency, surpassing prior guidance of approximately 3%. This performance was driven by improved market conditions, particularly in China and emerging markets, and effective execution of the Spinnaker sales and marketing program. The company also achieved excellent adjusted EPS growth of 14% year-over-year, reaching $11.46.

    02

    Geographic Strength and Emerging Markets

    Asia/Rest of World demonstrated very strong performance with 9% organic growth, including China, which also grew 9% and exceeded expectations. Emerging markets outside of China, representing approximately 18% of total sales, grew high single digits. Europe delivered solid growth of 4% organically, while Americas grew 1% organically, partially offset by project timing in food retail and transportation and logistics.

    03

    Product Area Performance

    Laboratory sales increased 4% organically, benefiting from recent innovations and strong demand in biopharma, semiconductor, advanced materials, and battery segments. Core industrial grew 4% organically, driven by automation solutions. Product inspection organic sales growth was modest at 1% due to project timing but is expected to accelerate in the second half. Food retail sales grew 11% due to project activity timing.

    04

    Margin Expansion and Profitability

    Adjusted gross margin expanded 90 basis points to 59.3% in Q2, excluding the impact of foreign currency and acquisitions. This expansion was primarily driven by favorable price realization, lower tariff rates compared to the prior year, volume growth, and productivity initiatives, partially offset by higher transportation costs. Adjusted operating margin increased 100 basis points, excluding currency, to 29.3%.

    05

    Strategic Focus and Outlook

    The company remains optimistic about gradual market improvement and is focused on capitalizing on global trends in automation, digitalization, and onshoring investments. Management expressed confidence in continued solid financial performance through strong execution of strategic initiatives, leveraging its sophisticated Spinnaker program, and an innovative product portfolio, positioning the company well regardless of the macro environment.

    06

    Innovation and Digitalization Initiatives

    Mettler-Toledo's investments in innovation, such as the LabX software platform and AI-supported knowledge bases for service engineers, are driving growth and enhancing customer loyalty. These digital tools provide unique real-time business insights, enabling agile targeting of opportunities in hot segments like bioprocessing, GLP-1s, semiconductor, and battery, and improving service efficiency and first-fixed ratios.

    07

    Impact of Pharmacopoeia Revisions

    Recent revisions to the U.S., Japanese, and China Pharmacopoeia regarding weighing regulations are driving incremental growth for the company. Mettler-Toledo is well-positioned with its recently launched portfolio of new lab balances to help customers comply with these updated regulations, contributing to the positive momentum in the lab business.

    AI-generated summary of the company’s earnings call. Not investment advice.